Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Biology and normal function of factor VIII and factor IX

W Keith Hoots, MD
Amy D Shapiro, MD
Section Editor
Lawrence LK Leung, MD
Deputy Editor
Jennifer S Tirnauer, MD


Hemostasis is the process of blood clot formation at the site of vessel injury. This process begins with the formation of the platelet plug, followed by activation of the clotting cascade and propagation of the clot. The central feature of the clotting cascade is its sequential activation of a series of proenzymes or inactive precursor proteins (zymogens) to active enzymes, resulting in significant stepwise response amplification, (eg, the generation of a small number of factor VIIa molecules will activate many molecules of factor X, which in turn generates even larger numbers of thrombin molecules). The local generation of fibrin meshes and reinforces the platelet plug (figure 1).

One of the major multicomponent complexes in the coagulation cascade is the intrinsic X-ase (ten-ase). This complex consists of activated factor IX (factor IXa) as the protease, activated factor VIII (factor VIIIa), calcium, and phospholipids as the cofactors, and factor X as the substrate. Factor IXa can be generated by either factor XIa, activation of the intrinsic pathway, or by the tissue factor/factor VIIa complex. (See "Overview of hemostasis", section on 'Multicomponent complexes'.)

Although the generation or exposure of tissue factor at the wound site is the primary physiologic event in initiating clotting via the extrinsic pathway, the intrinsic pathway X-ase is important because of the limited amount of tissue factor generated in vivo and the presence of the tissue factor pathway inhibitor which, when complexed with factor Xa, inhibits the tissue factor/factor VIIa complex. Thus, sustained generation of thrombin depends upon the activation of factor IX and factor VIII. This process is amplified because factor VIII is activated by both factor Xa and thrombin [1,2] and factor IX is activated by factor XIa via thrombin, as well as by factor VIIa; as a result, a progressive increase in factor VIII and factor IX activation occurs as factor Xa and thrombin are formed.

The biology of factor VIII and factor IX is reviewed here. Deficiencies in either of these coagulation factors lead to hemophilia (hemophilia A and hemophilia B, respectively), which is discussed separately. (See "Clinical manifestations and diagnosis of hemophilia".)


The factor VIII gene is located on the X chromosome. It is one of the largest known genes, divided into 26 exons that span 186,000 base pairs [3,4]. Factor VIII is synthesized as a single chain polypeptide of 2351 amino acids. A 19-amino acid signal peptide is cleaved by a protease shortly after synthesis so that circulating plasma factor VIII is a heterodimer.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Jan 20, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A 1988; 85:2429.
  2. Butenas S, van 't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272:21527.
  3. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312:326.
  4. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312:342.
  5. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83:1978.
  6. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86:1811.
  7. Saenko EL, Ananyeva NM, Tuddenham EG, Kemball-Cook G. Factor VIII - novel insights into form and function. Br J Haematol 2002; 119:323.
  8. Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111:1240.
  9. Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92:3701.
  10. Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402:439.
  11. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269:11601.
  12. Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274:31000.
  13. Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000; 275:25774.
  14. Zhong D, Saenko EL, Shima M, et al. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92:136.
  15. Amano K, Sarkar R, Pemberton S, et al. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998; 91:538.
  16. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269:20522.
  17. O'Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem 1995; 270:27087.
  18. Lamphear BJ, Fay PJ. Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer. J Biol Chem 1992; 267:3725.
  19. Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78:256.
  20. Kaufman RJ, Pipe SW, Tagliavacca L, et al. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 1997; 8 Suppl 2:S3.
  21. Tuddenham E. In search of the source of factor VIII. Blood 2014; 123:3691.
  22. Fahs SA, Hille MT, Shi Q, et al. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014; 123:3706.
  23. Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.
  24. Koppelman SJ, van Hoeij M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87:2292.
  25. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82:1236.
  26. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263:10451.
  27. Tuley EA, Gaucher C, Jorieux S, et al. Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci U S A 1991; 88:6377.
  28. Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thromb Haemost 1997; 78:451.
  29. Jacquemin M, Lavend'homme R, Benhida A, et al. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000; 96:958.
  30. Jesty J, Spencer AK, Nemerson Y. The mechanism of activation of factor X. Kinetic control of alternative pathways leading to the formation of activated factor X. J Biol Chem 1974; 249:5614.
  31. Brandstetter H, Bauer M, Huber R, et al. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci U S A 1995; 92:9796.
  32. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46:103.
  33. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266:7353.
  34. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86:3035.
  35. Sun Y, Gailani D. Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 1996; 271:29023.
  36. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63:486.
  37. O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 2000; 95:1714.
  38. Dahlbäck B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999; 25:273.
  39. Bovenschen N, Rijken DC, Havekes LM, et al. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 2005; 3:1257.
  40. Sarafanov AG, Makogonenko EM, Pechik IV, et al. Identification of coagulation factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein. Biochemistry 2006; 45:1829.
  41. Lacroix-Desmazes S, Navarrete AM, André S, et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008; 112:240.
  42. Jorgensen MJ, Cantor AB, Furie BC, et al. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 1987; 48:185.
  43. Hubbard BR, Ulrich MM, Jacobs M, et al. Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site. Proc Natl Acad Sci U S A 1989; 86:6893.
  44. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53:505.
  45. Hughes PE, Handford PA, Austen DE, Brownlee GG. Protein engineering of the hydrophobic domain of human factor IX. Protein Eng 1994; 7:1121.
  46. Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991; 78:1637.
  47. Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Biochemistry 1995; 34:12126.
  48. Li L, Darden TA, Freedman SJ, et al. Refinement of the NMR solution structure of the gamma-carboxyglutamic acid domain of coagulation factor IX using molecular dynamics simulation with initial Ca2+ positions determined by a genetic algorithm. Biochemistry 1997; 36:2132.
  49. Freedman SJ, Blostein MD, Baleja JD, et al. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem 1996; 271:16227.
  50. Rao Z, Handford P, Mayhew M, et al. The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell 1995; 82:131.
  51. Zhong D, Smith KJ, Birktoft JJ, Bajaj SP. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. Proc Natl Acad Sci U S A 1994; 91:3574.
  52. Wong MY, Gurr JA, Walsh PN. The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex. Biochemistry 1999; 38:8948.
  53. Ahmad SS, Wong MY, Rawala R, et al. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex. Biochemistry 1998; 37:1671.
  54. Vidaud M, Chabret C, Gazengel C, et al. A de novo intragenic deletion of the potential EGF domain of the factor IX gene in a family with severe hemophilia B. Blood 1986; 68:961.
  55. Hertzberg MS, Facey SL, Hogg PJ. An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa. Blood 1999; 94:156.
  56. Cheung WF, van den Born J, Kühn K, et al. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci U S A 1996; 93:11068.
  57. Bode W, Brandstetter H, Mather T, Stubbs MT. Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C. Thromb Haemost 1997; 78:501.
  58. Perona JJ, Craik CS. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem 1997; 272:29987.
  59. Kolkman JA, Christophe OD, Lenting PJ, Mertens K. Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction. J Biol Chem 1999; 274:29087.
  60. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977; 74:5260.
  61. Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63:1338.
  62. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30:10363.
  63. Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61:1528.
  64. Mann KG, Nesheim ME, Church WR, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76:1.
  65. Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37.
  66. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361:1671.
  67. Lin CN, Kao CY, Miao CH, et al. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost 2010; 8:1773.